Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 16/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.41 |
| ▸ | HPGD | P15428 | 11/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526646 | 0.92 | HSD17B10 (0.44) | HSD17B10ALDH1A1HPGDCYP2D6TSHR | |
| SCHEMBL4512984 | 0.82 | HSD17B10 (0.49) | HSD17B10ALDH1A1HPGDCYP2D6TSHR | |
| SCHEMBL4533134 | 0.79 | HSD17B10 (0.48) | HSD17B10ALDH1A1HPGDCYP2D6TSHR | |
| SCHEMBL13633950 | 0.78 | PAK4 (0.46) | HSD17B10ALDH1A1HPGDCYP2D6TSHR | |
| SCHEMBL4524523 | 0.78 | WHR1 (0.46) | — | |
| SCHEMBL4511804 | 0.77 | ALDH1A1 (0.44) | HSD17B10ALDH1A1HPGDCYP2D6TSHR | |
| SCHEMBL4529942 | 0.72 | PAK4 (0.39) | HSD17B10TSHRKMT2A | |
| SCHEMBL4524546 | 0.72 | WHR1 (0.46) | HSD17B10USP2CYP3A4CYP2C19 | |
| SCHEMBL4513370 | 0.71 | ABCG2 (0.36) | — | |
| SCHEMBL4529415 | 0.70 | WHR1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | HSD17B10 944/4885ALDH1A1 772/4885HPGD 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.